AstraZeneca
Sun Pharma agree deal to distribute AstraZeneca type-2 diabetes drug in India
March 24, 2016Sales and Marketing AstraZeneca, India, Sun Pharma, diabetes, oxra, type 2, type-2
Sun Pharma has agreed a deal with AstraZeneca to promote and distribute their type-2 diabetes drug, dapagliflozin, in India. Marketed …
AstraZeneca’s Brilinta fails to best aspirin in treating stroke patients
March 23, 2016Research and Development AstraZeneca, Brilinta, stroke
AstraZeneca has announced top-line results from the Phase III SOCRATES trial, confirming that twice-daily doses of its drug Brilinta (ticagrelor) failed …
AstraZeneca buys rights to Orexo respiratory programme
March 21, 2016Sales and Marketing AstraZeneca, COPD, asthma, orexo
AstraZeneca has bought the rights to a respiratory programme from Sweden’s Orexo for $5 million. The deal centres on the …
AZ drug gets orphan status for rare inflammatory disease
March 9, 2016Research and Development AstraZeneca, MEDI-551, MedImmune, orphan drug
AstraZeneca’s biologics R&D arm MedImmune has been granted Orphan Drug Designation by the FDA for its investigational anti-CD19 monoclonal antibody, …
AstraZeneca’s Faslodex gets US FDA nod in combination treatment for breast cancer
March 8, 2016Manufacturing and Production, Research and Development AstraZeneca, Faslodex, US FDA, palbociclib
UK drug-maker AstraZeneca said the US Food and Drug Administration (FDA) has approved a new indication expanding the use of …
Delivering successful new drugs
March 1, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, patents, pharma
Pharma companies are struggling with challenges specific to their industry. Patents for many drugs, that had created massive amounts of …
AstraZeneca licenses European rights to constipation drug for $70m
March 1, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, EU, Japan, Luke Miles, ProStrakan Group, constipation drug, moventig
AstraZeneca said on Tuesday it has agreed to licence rights to its constipation drug Moventig to Japan’s ProStrakan Group for …
AstraZeneca announces tremelimumab setback in mesothelioma test
March 1, 2016Manufacturing and Production, Research and Development AstraZeneca, Cancer, MedImmune, tremelimumab
AstraZeneca and its global biologics research and development arm, MedImmune, have announced a setback in the result of their Phase …
EMA recommends AZ/Acerta drug for orphan status in three indications
February 25, 2016Research and Development AstraZeneca, EMA, Orphan Drugs
The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has recommended AstraZeneca and Acerta’s acalabrutinib (ACP-196) for designation …
AZ’s durvalumab awarded breakthrough status in bladder cancer
February 18, 2016Research and Development AstraZeneca, FDA, bladder cancer
AstraZeneca, and its biologics/R&D arm MedImmune, have won FDA Breakthrough Therapy status for their bladder cancer drug durvalumab (MEDI4736), which …
AZ warns of patent losses as revenues fall
February 4, 2016Medical Communications, Sales and Marketing AstraZeneca, Crestor, Zurampic
AstraZeneca announced full-year revenues down 7% to $24.7 billion, and Q4 sales down 5% to $6.4 billion, as the London-based …
AstraZeneca’s Tagrisso gets EU lung cancer sign-off
February 4, 2016Sales and Marketing AstraZeneca, European Commission, NSCLC, Tagrisso, non-small cell lung cancer, osimertinib
The European Commission (EC) has granted conditional marketing authorisation to AstraZeneca’s Tagrisso to treat locally advanced or metastatic non-small cell …
AZ’s Lynparza gets prostate cancer breakthrough status
January 28, 2016Sales and Marketing AstraZeneca, Breakthrough Therapy Designation, FDA, lynparza, olaparib, prostate cancer
AstraZeneca’s Lynparza has been granted breakthrough therapy designation by the FDA as a monotherapy for the treatment of a specific …
Big pharma and UK universities launch £40m innovation fund
January 25, 2016Research and Development, Sales and Marketing Apollo, AstraZeneca, GSK, GlaxoSmithKline, Johnson & Johson, UCL, University College London, University of Cambridge, collaboration, imperial college london, joint venture
A consortium of big pharma companies and university with world-leading medical research facilities is to invest £40 million, to “significantly …
AstraZeneca and MedImmune in oncology research deals
January 12, 2016Manufacturing and Production, Research and Development AstraZeneca, Incyte, MedImmune, Moderna Therapeutics
AstraZeneca and its biologics arm MedImmune are launching new agreements with partner companies, to develop new targets for cancer, and …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
